Incb009471
Webβ-Thromboglobulin ( β-TG ), or beta-thromboglobulin, is a chemokine protein secreted by platelets. [1] [2] It is a type of chemokine (C-X-C motif) ligand 7. [3] Along with platelet factor 4 (PF4), β-TG is one of the best-characterized platelet-specific proteins. WebSafety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients - No Study Results Posted.
Incb009471
Did you know?
Web--The safety/activity of other once-daily doses of INCB009471 is under investigation--Phase 2b studies are planned of one (or more) doses Background Information: INCB9471 … WebDescription: INCB-9471 HCl, also known as INCB-009471, is an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity …
WebThe CCR5 antagonist INCB009471 has nanomolar activity against HIV-1 in vitro. This compound demonstrated potent and prolonged antiviral activity against R5-tropic HIV-1 when given 200 mg once daily dose for 14 days. These findings supported further clinical development of INCB009471 and they have since progressed to phase IIb clinical trials. WebSubjects will receive study medication (INCB009471) admnistered orally or placebo once daily with food for 14 days. Clinical safety laboratories, 12-lead electrocardiograms, physical examinations and virologic assessments, including viral load, viral tropism and CD4+ cell count determinations will be performed at the Screening visit and at ...
WebOct 24, 2006 · The primary objectives are: 1. Assess the safety and tolerability of 3 doses of INCB009471 or placebo when administered orally, once daily, as monotherapy for 14 days; 2. Determine the pharmacokinetics of 3 doses of INCB009471 or placebo when administered orally, once daily, as monotherapy for 14 days; 3. WebDownload scientific diagram INCB009471 Single-Dose Plasma Concentrations (Mean ± SE) from publication: Single and Multiple Dose Pharmacokinetics of INCB9471, a Potent …
WebMay 22, 2013 · INCB-9471 is a selective, reversible, small-molecule CCR5 coreceptor antagonist that binds to a CCR5 binding pocket that is different from what maraviroc binds to. INCB-9471prevents viral entry by inhibiting the interaction between HIV-1 gp120 and CCR5. INCB-9471 prevents CCR5-mediated viral entry via allosteric noncompetitive …
fmc fsmc区别WebTato studie vyhodnocuje bezpečnost, farmakokinetiku a účinnost antagonisty CCR5 INCB009471 u pacientů infikovaných HIV-1, kteří dosud neužívali ... Registr klinických hodnocení. ICH GCP. greensboro nc sign permitsWebINCB009471 Single-Dose Plasma Concentrations (Mean ± SE) Source publication Single and Multiple Dose Pharmacokinetics of INCB9471, a Potent Single and Multiple Dose Pharmacokinetics of INCB9471,... fmc friscoWebSafety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-Tropic HIV Infected Patients : Official Title: A Randomized, Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV ... greensboro nc sit ins factsWebFunkcija. Protein kodiran ovim genom, CXCL5 je mali citokin u porodici CXC hemokina koji je također poznat kao peptid 78 (ENA-78) za aktiviranje neutrofila izvedenih iz epitela.Proizvodi se nakon stimulacije ćelija upalnim citokinima interleukinom-1 ili faktorom nekroze tumora-alfa. Ekspresija CXCL5 je također uočena kod eozinofila i može se inhibirati … greensboro nc sister citiesWebSafety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients. Latest version (submitted March 22, 2024) on ClinicalTrials.gov. A study version is represented by a row in the table. Select two study versions to compare. One each from columns A and B. fmc fundingWebOct 24, 2006 · This study will evaluate the safety, pharmacokinetics and efficacy of the CCR5 antagonist INCB009471 in HIV-1 infected patients who are antiretroviral therapy … fmcf victoria